|
|
|
|
Archives
|
Entry
|
Author
|
Date
|
Location
|
|
NanoString Forges Closer Ties With Broad Institute to See What Genetic Tool Can Really Do
|
Luke Timmerman |
11/18/09 |
Seattle
|
|
Aileron’s New Class of Drugs Shown to Get Inside Cells to Block Prime Cancer Target
|
Luke Timmerman |
11/11/09 |
Boston
|
|
Who Will Create the Future of San Diego Biotech? Xconomy Event Will Gather Star Innovators From Inside and Outside the Region
|
Luke Timmerman |
11/10/09 |
San Diego
|
|
Santaris Nabs Isis, Amgen Vets
|
Luke Timmerman |
10/28/09 |
San Diego
|
|
Yale startup 3PrimiR Raises $2.1M
|
Ryan McBride |
09/16/09 |
Boston
|
|
MicroRNA Drug Developer Santaris Establishes Toehold in San Diego With Isis Veteran
|
Luke Timmerman |
09/16/09 |
San Diego
|
|
$50M for Helicon, Cytori Bulks Up, Avanir Awaits Trial Results, & More San Diego Life Sciences News
|
Eric Hal Schwartz |
07/30/09 |
San Diego
|
|
Alnylam and Isis’ Offspring, Regulus, Keeps Pushing on Biology’s ‘Bleeding Edge’
|
Luke Timmerman |
07/28/09 |
San Diego
|
|
Archemix Signs MicroRNA Deal
|
Luke Timmerman |
07/23/09 |
Boston
|
|
Regulus Hits GSK Milestone
|
Luke Timmerman |
05/14/09 |
San Diego
|
|
Leroy Hood, ISB Scientists Spot Genes For “Mad Cow” Disease; May Lead to Diagnostic Test
|
Luke Timmerman |
03/24/09 |
Seattle
|
|
Alnylam Looks to Spinoffs To Unleash RNAi Technologies for Stem Cells, Vaccines
|
Luke Timmerman |
02/18/09 |
Boston
|
|
Regulus, Leading Developer of MicroRNA Drugs, Prepares to Get Independence from Alnylam and Isis
|
Luke Timmerman |
01/21/09 |
San Diego
|
|
MicroRNA Leaps Ahead: Alnylam-Isis Venture, Regulus, Shows Its Drug Works in Animals With Heart Failure
|
Luke Timmerman |
11/30/08 |
San Diego
|
|
Alnylam–Isis Venture Regulus, Leader in MicroRNA Drugs, Aspires to Create New Paradigm of Treatments
|
Luke Timmerman |
10/24/08 |
San Diego
|
|
Dendreon Proceeds With Prostate Cancer Clinical Trials, AXI Gets Oil from Algae, PATH Prepares to Launch “Ultra Rice,” & More Deals News
|
Gregory T. Huang |
08/18/08 |
Seattle
|
|
Accelerator Bankrolls New Company, Mirina, To Develop MicroRNA-Blocking Drugs
|
Luke Timmerman |
08/15/08 |
Seattle
|
|
Rocky Mountain High: Atlas Venture Is Banking on microRNA for Miragen
|
Gregory T. Huang |
05/22/08 |
Boston
|
|
Alnylam Joint Venture Regulus Inks Deal with GSK Worth up to $600 Million
|
Erik Mellgren |
04/17/08 |
Boston
|
|
Page 2 of
2 |
« previous page |
Business, life sciences, and technology news — covering Boston, Seattle, San Diego, Detroit, San Francisco, New York and beyond.
© 2007-2012, Xconomy, Inc.
Xconomy is a registered service mark of Xconomy, Inc.
All rights reserved.
Site produced by Andrew Koyfman with design from Rob Hunter.
